exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087652 RNA Name: hsa-miR-124-3p RNA Type: miRNA Chromosome: chr8 Starnd: + Coordinate: Start Site(bp): 64379210 End Site(bp): 64379231 External Links: hsa-miR-124-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CDH1 chr16 68737292 68835541 + MDK chr11 46380756 46383837 + TRAPPC10 chr21 44012309 44106552 + COL12A1 chr6 75084326 75206053 - RANBP10 chr16 67723070 67806652 - TSEN54 chr17 75516060 75524735 + ZCCHC24 chr10 79382325 79445624 - ASF1B chr19 14119512 14136613 - RPS10-NUDT3 chr6 34284887 34426071 - JAG1 chr20 10637684 10673999 - RPS6KA3 chrX 20149911 20267519 - CTDSP1 chr2 218398256 218405941 + NUDT3 chr6 34279679 34392669 - FAM102A chr9 127940582 127980989 - MMS22L chr6 97142161 97283217 - EPHB4 chr7 100802565 100827523 - ANGPTL2 chr9 127087348 127122635 - BLOC1S5-TXNDC5 chr6 7881522 8064364 - PAPSS2 chr10 87659613 87747705 + C20orf27 chr20 3753508 3768387 - MOB4 chr2 197515571 197553699 + SCAMP2 chr15 74843730 74873365 - CDKN2A chr9 21967753 21995301 - G3BP2 chr4 75642782 75724525 - ZSCAN22 chr19 58326994 58342332 + ANKRD52 chr12 56237807 56258384 - NFAT5 chr16 69565094 69704666 + CREB3L2 chr7 137874979 138002086 - CLASP1 chr2 121337776 121649587 - MLLT1 chr19 6210381 6279975 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001186 chr21 35475133 35475818 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008040.1 chr3 169939353 169966734 - AC069281.2 chr7 100572232 100578700 - AC084082.1 chr8 66112667 66126632 + FGD5-AS1 chr3 14920347 14948424 - KCNQ1OT1 chr11 2608328 2699994 - LINC00240 chr6 26956932 27059749 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + SNHG16 chr17 76557764 76565348 + TMEM147-AS1 chr19 35540738 35546029 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.